[HTML][HTML] Molecular pathways and therapeutic targets in lung cancer
E Shtivelman, T Hensing, GR Simon, PA Dennis… - Oncotarget, 2014 - ncbi.nlm.nih.gov
Lung cancer is still the leading cause of cancer death worldwide. Both histologically and
molecularly lung cancer is heterogeneous. This review summarizes the current knowledge …
molecularly lung cancer is heterogeneous. This review summarizes the current knowledge …
Overcoming drug resistance to receptor tyrosine kinase inhibitors: Learning from lung cancer
M Kuwano, K Sonoda, Y Murakami, K Watari… - Pharmacology & …, 2016 - Elsevier
There are various receptor tyrosine kinase (TK)-targeted drugs that are currently used in the
treatment of patients with non-small cell lung cancer (NSCLC). Among them, the epidermal …
treatment of patients with non-small cell lung cancer (NSCLC). Among them, the epidermal …
Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: meta-analysis of 153 cohorts with 15,713 patients: meta …
Purpose Pneumonitis is a significant toxicity of EGFR tyrosine kinase inhibitors (EGFR-TKI)
in non-small-cell lung cancer (NSCLC) patients. We studied the incidence of pneumonitis in …
in non-small-cell lung cancer (NSCLC) patients. We studied the incidence of pneumonitis in …
CD44 inhibition attenuates EGFR signaling and enhances cisplatin sensitivity in human EGFR wild‑type non‑small‑cell lung cancer cells
J Yin, H Zhang, X Wu, Y Zhang… - International …, 2020 - spandidos-publications.com
Abstract Cluster of differentiation 44 (CD44) as a transmembrane glycoprotein is found to be
expressed in non‑small cell lung cancer (NSCLC), is significantly associated with NSLC …
expressed in non‑small cell lung cancer (NSCLC), is significantly associated with NSLC …
Population pharmacokinetics/pharmacodynamics of erlotinib and pharmacogenomic analysis of plasma and cerebrospinal fluid drug concentrations in Japanese …
M Fukudo, Y Ikemi, Y Togashi, K Masago… - Clinical …, 2013 - Springer
Background Erlotinib shows large inter-patient pharmacokinetic variability, but the impact of
early drug exposure and genetic variations on the clinical outcomes of erlotinib remains fully …
early drug exposure and genetic variations on the clinical outcomes of erlotinib remains fully …
Personalized targeted therapy for lung cancer
Lung cancer has long been recognized as an extremely heterogeneous disease, since its
development is unique in every patient in terms of clinical characterizations, prognosis …
development is unique in every patient in terms of clinical characterizations, prognosis …
Efficacy of epidermal growth factor receptor inhibitors versus chemotherapy as second-line treatment in advanced non-small-cell lung cancer with wild-type EGFR: a …
N Zhao, X Zhang, H Yan, J Yang, Y Wu - Lung Cancer, 2014 - Elsevier
Background EGFR mutation status is closely related to the efficacy of EGFR-TKIs in
advanced non-small cell lung cancer (NSCLC). EGFR-TKIs have become the standard first …
advanced non-small cell lung cancer (NSCLC). EGFR-TKIs have become the standard first …
Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer
G Sette, V Salvati, M Mottolese, P Visca, E Gallo… - Cell death & …, 2015 - nature.com
Tyrosine kinase inhibitors (TKIs) have shown strong activity against non-small-cell lung
cancer (NSCLC) patients harboring activating epidermal growth factor receptor (EGFR) …
cancer (NSCLC) patients harboring activating epidermal growth factor receptor (EGFR) …
EGFR mutation frequency and effectiveness of erlotinib: a prospective observational study in Danish patients with non-small cell lung cancer
Objectives In 2008, we initiated a prospective study to explore the frequency and predictive
value of epidermal growth factor receptor (EGFR) mutations in an unselected population of …
value of epidermal growth factor receptor (EGFR) mutations in an unselected population of …
Eye, hepatobiliary, and renal disorders of erlotinib in patients with non-small-cell lung cancer: A meta-analysis
HD Choi, MJ Chang - PloS one, 2020 - journals.plos.org
Background Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors used to treat EGFR mutation positive non-small-cell lung cancer (NSCLC). Skin …
inhibitors used to treat EGFR mutation positive non-small-cell lung cancer (NSCLC). Skin …